Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
Cancer Res Treat. 2018;50(3):835-842.   Published online 2017 Aug 29     DOI: https://doi.org/10.4143/crt.2017.303
Citations to this article as recorded by Crossref logo
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino
Critical Reviews in Oncology/Hematology.2021; 160: 103299.     CrossRef
Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang
Journal of Thoracic Oncology.2020; 15(6): 962.     CrossRef
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu
Pharmacology & Therapeutics.2020; 206: 107438.     CrossRef
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
Critical Reviews in Oncology/Hematology.2020; 148: 102906.     CrossRef
Mutation Variants and Co‐Mutations as Genomic Modifiers of Response to Afatinib inHER2‐Mutant Lung Adenocarcinoma
Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang, Xiaoyan Ma, Minghui Wang, Wenjing Wang, Songhui Zhao, Kai Wang, Song Gao, Li Zhang
The Oncologist.2020;[Epub]     CrossRef
Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Teresa Moran, Alvaro Taus, Edurne Arriola, Carlos Aguado, Manuel Dómine, Ana Gómez Rueda, Antonio Calles, Susana Cedrés, Nuria Viñolas, Dolores Isla, Ramón Palmero, María Sereno, Victor Diaz, Oscar Juan, Raquel Marsé, Paloma Martín Martorell, José Miguel
Clinical Lung Cancer.2020; 21(5): 428.     CrossRef
HER2-positive advanced breast cancer treatment in 2020
Marcelle G. Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja
Cancer Treatment Reviews.2020; 88: 102033.     CrossRef
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, Anthony Gonçalves
Cancers.2020; 12(6): 1573.     CrossRef
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang, Shucai Zhang
Frontiers in Oncology.2020;[Epub]     CrossRef
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
Breast Cancer Research and Treatment.2020; 184(3): 743.     CrossRef
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Jordi Remon, Lizza E.L. Hendriks, Andres F. Cardona, Benjamin Besse
Cancer Treatment Reviews.2020; 90: 102105.     CrossRef
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni
Critical Reviews in Oncology/Hematology.2020; 156: 103119.     CrossRef
Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
Xue Yang, Dapeng Wu, Shengli Yuan
Technology in Cancer Research & Treatment.2020; 19: 153303382096214.     CrossRef
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
Cancers.2020; 12(11): 3249.     CrossRef
Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo
Gastrointestinal Disorders.2020; 3(1): 1.     CrossRef
Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
Apurva Pandey, Adam M. Brufsky
Clinical Breast Cancer.2019; 19(1): e7.     CrossRef
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
Debasis Das, Jian Hong
European Journal of Medicinal Chemistry.2019; 170: 55.     CrossRef
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Wei Jiang, Meiju Ji
Seminars in Cancer Biology.2019; 59: 3.     CrossRef
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
Tae-Yong Kim, Hye Sook Han, Keun-Wook Lee, Dae Young Zang, Sun Young Rha, Young Iee Park, Jin-Soo Kim, Kyung-Hun Lee, Se Hoon Park, Eun-Kee Song, Soo-A Jung, NaMi Lee, Yeul Hong Kim, Jae Yong Cho, Yung-Jue Bang
Gastric Cancer.2019; 22(6): 1206.     CrossRef
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown
Cancers.2019; 11(6): 737.     CrossRef
Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positi
Ji‐Yeon Kim, Eunjin Lee, Kyunghee Park, Hae Hyun Jung, Woong‐Yang Park, Kyung‐Hun Lee, Joohyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee Hyun Kim, Ki Hyeong Lee, Seock‐Ah Im, Yeon Hee Park
International Journal of Cancer.2019; 145(6): 1669.     CrossRef
Emergence ofERBB2Mutation as a Biomarker and an Actionable Target in Solid Cancers
Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha
The Oncologist.2019;[Epub]     CrossRef
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Makoto Suzuki, Pasi A. Jänne, Tetsuya Mitsudomi
Lung Cancer.2018; 126: 72.     CrossRef
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Yeon Hee Park, Kyung-Hun Lee, Joo Hyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee-Hyun Kim, Ki Hyeong Lee, Jin Seok Ahn, Tae-Yong Kim, Gun Min Kim, In Hae Park, Sung-Bae Kim, Se Hyun Kim, Hye Sook Han, Young-Hyuck Im, Jin-Hee Ahn, Jung-Yong Kim, Jahoon Kang
International Journal of Cancer.2018; 143(12): 3240.     CrossRef
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Clinical Cancer Research.2018; 24(24): 6548.     CrossRef